IBDEI0YJ ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16214,2)
 ;;=^5001795
 ;;^UTILITY(U,$J,358.3,16215,0)
 ;;=C92.21^^61^727^8
 ;;^UTILITY(U,$J,358.3,16215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16215,1,3,0)
 ;;=3^Myeloid Leukemia BCR/ABL-neg,Atyp Chr,In Remission
 ;;^UTILITY(U,$J,358.3,16215,1,4,0)
 ;;=4^C92.21
 ;;^UTILITY(U,$J,358.3,16215,2)
 ;;=^5001796
 ;;^UTILITY(U,$J,358.3,16216,0)
 ;;=D46.9^^61^727^5
 ;;^UTILITY(U,$J,358.3,16216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16216,1,3,0)
 ;;=3^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,16216,1,4,0)
 ;;=4^D46.9
 ;;^UTILITY(U,$J,358.3,16216,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,16217,0)
 ;;=D45.^^61^727^12
 ;;^UTILITY(U,$J,358.3,16217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16217,1,3,0)
 ;;=3^Polycythemia Vera
 ;;^UTILITY(U,$J,358.3,16217,1,4,0)
 ;;=4^D45.
 ;;^UTILITY(U,$J,358.3,16217,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,16218,0)
 ;;=D75.1^^61^727^13
 ;;^UTILITY(U,$J,358.3,16218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16218,1,3,0)
 ;;=3^Polycythemia,Secondary
 ;;^UTILITY(U,$J,358.3,16218,1,4,0)
 ;;=4^D75.1
 ;;^UTILITY(U,$J,358.3,16218,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,16219,0)
 ;;=D68.51^^61^727^1
 ;;^UTILITY(U,$J,358.3,16219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16219,1,3,0)
 ;;=3^Activated Protein C Resistance
 ;;^UTILITY(U,$J,358.3,16219,1,4,0)
 ;;=4^D68.51
 ;;^UTILITY(U,$J,358.3,16219,2)
 ;;=^5002358
 ;;^UTILITY(U,$J,358.3,16220,0)
 ;;=D68.52^^61^727^16
 ;;^UTILITY(U,$J,358.3,16220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16220,1,3,0)
 ;;=3^Prothrombin Gene Mutation
 ;;^UTILITY(U,$J,358.3,16220,1,4,0)
 ;;=4^D68.52
 ;;^UTILITY(U,$J,358.3,16220,2)
 ;;=^5002359
 ;;^UTILITY(U,$J,358.3,16221,0)
 ;;=D68.59^^61^727^17
 ;;^UTILITY(U,$J,358.3,16221,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16221,1,3,0)
 ;;=3^Thrombophilia,Primary,Other
 ;;^UTILITY(U,$J,358.3,16221,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,16221,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,16222,0)
 ;;=D68.62^^61^727^2
 ;;^UTILITY(U,$J,358.3,16222,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16222,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,16222,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,16222,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,16223,0)
 ;;=D72.9^^61^727^18
 ;;^UTILITY(U,$J,358.3,16223,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16223,1,3,0)
 ;;=3^White Blood Cell Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,16223,1,4,0)
 ;;=4^D72.9
 ;;^UTILITY(U,$J,358.3,16223,2)
 ;;=^5002381
 ;;^UTILITY(U,$J,358.3,16224,0)
 ;;=Z85.038^^61^728^15
 ;;^UTILITY(U,$J,358.3,16224,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16224,1,3,0)
 ;;=3^Personal Hx Malig Neop Large Intestine
 ;;^UTILITY(U,$J,358.3,16224,1,4,0)
 ;;=4^Z85.038
 ;;^UTILITY(U,$J,358.3,16224,2)
 ;;=^5063399
 ;;^UTILITY(U,$J,358.3,16225,0)
 ;;=Z85.51^^61^728^3
 ;;^UTILITY(U,$J,358.3,16225,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16225,1,3,0)
 ;;=3^Personal Hx Malig Neop Bladder
 ;;^UTILITY(U,$J,358.3,16225,1,4,0)
 ;;=4^Z85.51
 ;;^UTILITY(U,$J,358.3,16225,2)
 ;;=^5063428
 ;;^UTILITY(U,$J,358.3,16226,0)
 ;;=Z85.830^^61^728^4
 ;;^UTILITY(U,$J,358.3,16226,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16226,1,3,0)
 ;;=3^Personal Hx Malig Neop Bone
 ;;^UTILITY(U,$J,358.3,16226,1,4,0)
 ;;=4^Z85.830
 ;;^UTILITY(U,$J,358.3,16226,2)
 ;;=^5063444
 ;;^UTILITY(U,$J,358.3,16227,0)
 ;;=Z85.841^^61^728^5
 ;;^UTILITY(U,$J,358.3,16227,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16227,1,3,0)
 ;;=3^Personal Hx Malig Neop Brain
 ;;^UTILITY(U,$J,358.3,16227,1,4,0)
 ;;=4^Z85.841
 ;;^UTILITY(U,$J,358.3,16227,2)
 ;;=^5063447
